Signal from the log
Dren Bio
350 M$ · United States · Biotech
Dren Bio développe dibotatug, un anticorps qui vise CD94 pour éliminer seulement les cellules immunitaires malades, dans deux cancers du sang rares sans traitement approuvé, le lymphome T cytotoxique et la leucémie à grands lymphocytes granuleux. Plus de 300 patients l'ont reçu dans l'essai de phase 1/2, selon la société.
Verified
Announced on , logged by the watch of 29 October 2026.
- Operation
- Funding round
- Announced amount
- 350 M$
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Juvia Group , Lightspeed Venture Partners , with Mirae Asset Capital Life Science , General Catalyst , Cormorant Asset Management , OrbiMed
Provenance
Source businesswire,endpoints
Logged on 29 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.